Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Shanghai - Delayed Quote CNY

BIO (600201.SS)

Compare
7.11
-0.03
(-0.42%)
At close: April 11 at 3:00:03 PM GMT+8
Loading Chart for 600201.SS
  • Previous Close 7.14
  • Open 7.08
  • Bid 7.09 x --
  • Ask 7.12 x --
  • Day's Range 6.94 - 7.27
  • 52 Week Range 5.62 - 10.95
  • Volume 26,574,090
  • Avg. Volume 22,311,691
  • Market Cap (intraday) 7.966B
  • Beta (5Y Monthly) 0.76
  • PE Ratio (TTM) 47.40
  • EPS (TTM) 0.15
  • Earnings Date --
  • Forward Dividend & Yield 0.08 (1.13%)
  • Ex-Dividend Date Jul 15, 2024
  • 1y Target Est --

Jinyu Bio-technology Co., Ltd. engages in the research and development, production, and sale of veterinary products in China. Its product portfolio includes Jinyu Baoling, Yangzhou Youbang, and Liaoning Yikang animal vaccines for the prevention of foot, porcine, mycoplasma pneumoniae, porcine reproductive and respiratory syndrome, porcine pseudorabies, pathogenic avian influenza, brucellosis bacterial disease, bovine viral diarrhea and mucosal, infectious rhinotracheitis, and other domestic animal diseases. The company was founded in 1992 and is headquartered in Hohhot, China.

www.jinyu.com.cn

1,654

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 600201.SS

View More

Performance Overview: 600201.SS

Trailing total returns as of 4/11/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

600201.SS
3.64%
SSE Composite Index (000001.SS)
3.39%

1-Year Return

600201.SS
20.84%
SSE Composite Index (000001.SS)
6.72%

3-Year Return

600201.SS
30.50%
SSE Composite Index (000001.SS)
2.24%

5-Year Return

600201.SS
66.28%
SSE Composite Index (000001.SS)
15.79%

Compare To: 600201.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 600201.SS

View More

Valuation Measures

Annual
As of 4/11/2025
  • Market Cap

    7.97B

  • Enterprise Value

    6.66B

  • Trailing P/E

    47.40

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    5.83

  • Price/Book (mrq)

    1.47

  • Enterprise Value/Revenue

    4.93

  • Enterprise Value/EBITDA

    36.22

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    12.21%

  • Return on Assets (ttm)

    0.98%

  • Return on Equity (ttm)

    2.90%

  • Revenue (ttm)

    1.35B

  • Net Income Avi to Common (ttm)

    164.86M

  • Diluted EPS (ttm)

    0.15

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.31B

  • Total Debt/Equity (mrq)

    0.06%

  • Levered Free Cash Flow (ttm)

    211.88M

Research Analysis: 600201.SS

View More

Company Insights: 600201.SS

Research Reports: 600201.SS

View More

People Also Watch